{"transactions":[{"id":722567,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":true}}],"security":"Stock Options","published_at":"2026-06-30T20:57:59.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":1284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 50% on September 30, 2026, and 50% on December 31, 2026."}],"balance_after":1284,"derivative":{"exercise_price":87.68,"expiration_date":"2036-06-26","underlying":"Common Stock","underlying_shares":1284},"source":{"system":"sec-edgar","filing":"0001437749-26-022164","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926022164/rdgdoc.xml","form_type":"4"}},{"id":741316,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-06-11T20:32:29.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":93750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April  16, 2026, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April  16, 2026, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001827505-26-000007","document":"form4-06112026_080625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000007/form4-06112026_080625.xml","form_type":"4"}},{"id":741315,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-06-11T20:32:29.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":68750},"source":{"system":"sec-edgar","filing":"0001827505-26-000007","document":"form4-06112026_080625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000007/form4-06112026_080625.xml","form_type":"4"}},{"id":741314,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-06-11T20:32:29.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 22, 2024, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 22, 2024, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001827505-26-000007","document":"form4-06112026_080625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000007/form4-06112026_080625.xml","form_type":"4"}},{"id":741313,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:32:29.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock (\"Company Option\") that was outstanding and unexercised immediately prior to the effective time of the Merger (the \"Effective Time\") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a 4 year period: 25% on June 24, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.51,"expiration_date":"2033-07-24","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001827505-26-000007","document":"form4-06112026_080625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000007/form4-06112026_080625.xml","form_type":"4"}},{"id":741312,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-11T20:32:29.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001827505-26-000007","document":"form4-06112026_080625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000007/form4-06112026_080625.xml","form_type":"4"}},{"id":761460,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-05-27T20:05:24.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 22, 2024, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 22, 2024, subject to continued service through each vesting date."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001827505-26-000005","document":"form4-05272026_040503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000005/form4-05272026_040503.xml","form_type":"4"}},{"id":761459,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:05:24.000Z","date":"2026-05-26","kind":"sale","planned":false,"acquired":false,"shares":1489,"price":26.7778,"value":39872.1442,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":59291,"source":{"system":"sec-edgar","filing":"0001827505-26-000005","document":"form4-05272026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000005/form4-05272026_040503.xml","form_type":"4"}},{"id":761458,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:05:24.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":60780,"source":{"system":"sec-edgar","filing":"0001827505-26-000005","document":"form4-05272026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000005/form4-05272026_040503.xml","form_type":"4"}},{"id":763362,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-05-26T23:34:34.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date."}],"balance_after":68750,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001827505-26-000004","document":"form4-05262026_110530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000004/form4-05262026_110530.xml","form_type":"4"}},{"id":763361,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-05-26T23:34:34.000Z","date":"2026-05-22","kind":"sale","planned":false,"acquired":false,"shares":1861,"price":26.7844,"value":49845.7684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":55780,"source":{"system":"sec-edgar","filing":"0001827505-26-000004","document":"form4-05262026_110530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000004/form4-05262026_110530.xml","form_type":"4"}},{"id":763360,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-05-26T23:34:34.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":57641,"source":{"system":"sec-edgar","filing":"0001827505-26-000004","document":"form4-05262026_110530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000004/form4-05262026_110530.xml","form_type":"4"}},{"id":804352,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-20T23:41:40.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date."}],"balance_after":93750,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001827505-26-000003","document":"form4-04202026_110435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000003/form4-04202026_110435.xml","form_type":"4"}},{"id":804351,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:41:40.000Z","date":"2026-04-17","kind":"sale","planned":false,"acquired":false,"shares":1862,"price":20.2163,"value":37642.7506,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":51391,"source":{"system":"sec-edgar","filing":"0001827505-26-000003","document":"form4-04202026_110435.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000003/form4-04202026_110435.xml","form_type":"4"}},{"id":804350,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:41:40.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":53253,"source":{"system":"sec-edgar","filing":"0001827505-26-000003","document":"form4-04202026_110435.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000003/form4-04202026_110435.xml","form_type":"4"}},{"id":884322,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-25T00:42:42.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date."}],"balance_after":45000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001827505-26-000002","document":"form4-02252026_120239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000002/form4-02252026_120239.xml","form_type":"4"}},{"id":884321,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-25T00:42:42.000Z","date":"2026-02-21","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001827505-26-000002","document":"form4-02252026_120239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000002/form4-02252026_120239.xml","form_type":"4"}},{"id":884320,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:42:42.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":3975,"price":15.5668,"value":61878.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5101 to $15.566982 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47003,"source":{"system":"sec-edgar","filing":"0001827505-26-000002","document":"form4-02252026_120239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000002/form4-02252026_120239.xml","form_type":"4"}},{"id":884319,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:42:42.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":50978,"source":{"system":"sec-edgar","filing":"0001827505-26-000002","document":"form4-02252026_120239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000002/form4-02252026_120239.xml","form_type":"4"}},{"id":884318,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:42:42.000Z","date":"2026-02-21","kind":"exercise","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":45978,"source":{"system":"sec-edgar","filing":"0001827505-26-000002","document":"form4-02252026_120239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000002/form4-02252026_120239.xml","form_type":"4"}},{"id":934060,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:11:12.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001827505-26-000001","document":"form4-01212026_090108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750526000001/form4-01212026_090108.xml","form_type":"4"}},{"id":980073,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-12-04T21:02:52.000Z","date":"2025-11-22","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001827505-25-000004","document":"form4-12042025_091248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750525000004/form4-12042025_091248.xml","form_type":"4"}},{"id":980072,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-12-04T21:02:52.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":81250,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001827505-25-000004","document":"form4-12042025_091248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750525000004/form4-12042025_091248.xml","form_type":"4"}},{"id":980071,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-12-04T21:02:52.000Z","date":"2025-11-24","kind":"sale","planned":false,"acquired":false,"shares":3813,"price":13.451,"value":51288.663,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":39728,"source":{"system":"sec-edgar","filing":"0001827505-25-000004","document":"form4-12042025_091248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750525000004/form4-12042025_091248.xml","form_type":"4"}},{"id":980070,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-12-04T21:02:52.000Z","date":"2025-11-22","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":43541,"source":{"system":"sec-edgar","filing":"0001827505-25-000004","document":"form4-12042025_091248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750525000004/form4-12042025_091248.xml","form_type":"4"}},{"id":980069,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-12-04T21:02:52.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":38541,"source":{"system":"sec-edgar","filing":"0001827505-25-000004","document":"form4-12042025_091248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000182750525000004/form4-12042025_091248.xml","form_type":"4"}},{"id":1055501,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-08-27T00:00:34.000Z","date":"2025-08-22","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":55000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-25-023075","document":"form4-08272025_120830.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000141588925023075/form4-08272025_120830.xml","form_type":"4"}},{"id":1055500,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-27T00:00:34.000Z","date":"2025-08-25","kind":"sale","planned":false,"acquired":false,"shares":1480,"price":13.42,"value":19861.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":32291,"source":{"system":"sec-edgar","filing":"0001415889-25-023075","document":"form4-08272025_120830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000141588925023075/form4-08272025_120830.xml","form_type":"4"}},{"id":1055499,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-27T00:00:34.000Z","date":"2025-08-22","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":33771,"source":{"system":"sec-edgar","filing":"0001415889-25-023075","document":"form4-08272025_120830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000141588925023075/form4-08272025_120830.xml","form_type":"4"}},{"id":1056640,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-08-26T01:33:50.000Z","date":"2025-08-21","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025,  subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025,  subject to continued service through each vesting date."}],"balance_after":87500,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001415889-25-022975","document":"form4-08262025_010847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000141588925022975/form4-08262025_010847.xml","form_type":"4"}},{"id":1056639,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-26T01:33:50.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":1864,"price":13.2228,"value":24647.2992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":28771,"source":{"system":"sec-edgar","filing":"0001415889-25-022975","document":"form4-08262025_010847.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000141588925022975/form4-08262025_010847.xml","form_type":"4"}},{"id":1056638,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-26T01:33:50.000Z","date":"2025-08-21","kind":"exercise","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":30635,"source":{"system":"sec-edgar","filing":"0001415889-25-022975","document":"form4-08262025_010847.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000141588925022975/form4-08262025_010847.xml","form_type":"4"}},{"id":2020007,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-14T01:50:24.000Z","date":"2023-02-12","kind":"tax_withholding","acquired":false,"shares":1456,"price":3.94,"value":5736.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units."}],"balance_after":38619,"source":{"system":"sec-edgar","filing":"0001689548-23-000051","document":"wf-form4_167633939597330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000051/wf-form4_167633939597330.xml","form_type":"4"}},{"id":2053775,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-18T00:38:18.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest over a four-year period, with 25% vesting on January 12, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date."}],"balance_after":120000,"derivative":{"exercise_price":2.96,"expiration_date":"2033-01-12","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001689548-23-000027","document":"wf-form4_167400228292631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000027/wf-form4_167400228292631.xml","form_type":"4"}},{"id":2054788,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-13T12:45:18.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":41085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ms. Sweeny opted to receive this option grant in lieu of a cash bonus for the fiscal year ended December 31, 2022."}],"balance_after":41085,"derivative":{"exercise_price":2.96,"exercise_date":"2023-01-12","expiration_date":"2033-01-12","underlying":"Common Stock","underlying_shares":41085},"source":{"system":"sec-edgar","filing":"0001689548-23-000016","document":"wf-form4_167361390389054.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000016/wf-form4_167361390389054.xml","form_type":"4"}},{"id":2058889,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-09T23:19:42.000Z","date":"2023-01-07","kind":"tax_withholding","acquired":false,"shares":2079,"price":2.52,"value":5239.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units."}],"balance_after":40075,"source":{"system":"sec-edgar","filing":"0001689548-23-000008","document":"wf-form4_167330636859995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000008/wf-form4_167330636859995.xml","form_type":"4"}},{"id":2222084,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T20:50:30.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest over a four-year period, with 25% vesting on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date."}],"balance_after":65000,"derivative":{"exercise_price":2.12,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001689548-22-000093","document":"wf-form4_165610381162995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000093/wf-form4_165610381162995.xml","form_type":"4"}},{"id":2265745,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-05-18T21:21:52.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":2587,"price":8.798,"value":22760.426,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":42154,"source":{"system":"sec-edgar","filing":"0001689548-22-000040","document":"wf-form4_165290886348034.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000040/wf-form4_165290886348034.xml","form_type":"4"}},{"id":2394575,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-16T00:40:34.000Z","date":"2022-02-12","kind":"tax_withholding","acquired":false,"shares":1233,"price":12.85,"value":15844.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units."}],"balance_after":39567,"source":{"system":"sec-edgar","filing":"0001689548-22-000008","document":"wf-form4_164497200236409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000008/wf-form4_164497200236409.xml","form_type":"4"}},{"id":2437780,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-11T21:09:45.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option vest over a four-year period, with 25% vesting on January 7, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date."}],"balance_after":84000,"derivative":{"exercise_price":18.11,"expiration_date":"2032-01-07","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001104659-22-003164","document":"tm222494-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000110465922003164/tm222494-6_4seq1.xml","form_type":"4"}},{"id":2437779,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-11T21:09:45.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ms. Sweeny was awarded 24,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on January 7, 2023, subject to the reporting person's continued service through each vesting date. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":40800,"source":{"system":"sec-edgar","filing":"0001104659-22-003164","document":"tm222494-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000110465922003164/tm222494-6_4seq1.xml","form_type":"4"}},{"id":2854895,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-17T21:57:40.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":58880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option vest over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date of February 12, 2021 and the remaining 75% vesting in 36 equal monthly installments following such first anniversary, subject to the reporting person's continued service through each vesting date."}],"balance_after":58880,"derivative":{"exercise_price":52.53,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":58880},"source":{"system":"sec-edgar","filing":"0001689548-21-000013","document":"wf-form4_161359904369402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954821000013/wf-form4_161359904369402.xml","form_type":"4"}},{"id":2854894,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":34404,"kind":"person","name":"Sweeny Nicole","position":1,"cik":"0001827505","reported_name":"Sweeny Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-17T21:57:40.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ms. Sweeny was awarded 16,800 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of February 12, 2021. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":16800,"source":{"system":"sec-edgar","filing":"0001689548-21-000013","document":"wf-form4_161359904369402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954821000013/wf-form4_161359904369402.xml","form_type":"4"}}]}